Literature DB >> 19673890

Human epithelial ovarian carcinoma cell-derived cytokines cooperatively induce activated CD4+CD25-CD45RA+ naïve T cells to express forkhead box protein 3 and exhibit suppressive ability in vitro.

Xiaofeng Zhao1, Feng Ye, Lili Chen, Weiguo Lu, Xing Xie.   

Abstract

Regulatory T cells play an important role in tumor escape from host antitumor immunity. Increased frequencies of CD4(+)CD25(+) regulatory T cells have been documented in the tumor sites, malignant effusions, and peripheral blood of patients with ovarian carcinoma. However, the mechanism involved remains unclear. In the present study, we collected high-purity human CD4(+)CD25(-)CD45RA(+) naïve T cells by microbead cell separation. These cells did not express FOXP3 by single-cell analysis, and few cells expressed FOXP3 when they were activated with anti-CD3/CD28 dual signal. However, more cells expressed FOXP3 when the supernatant of human epithelial ovarian carcinoma cell culture was added, yet not the supernatant of normal human ovarian surface epithelia cell culture. Neutralization assays revealed that neutralizing antibody against transforming growth factor beta (TGF-beta), interleukin-10, and interleukin-4 did not abrogate elevated FOXP3 expression induced by carcinoma cell culture supernatant, whereas neutralizing leukemia inhibitory factor (LIF) partially abrogated FOXP3 expression, but LIF alone could not increase FOXP3 expression in activated naïve T cells. Further, an in vitro coculture suppression assay showed that these cells could suppress the proliferation of autologous CD4(+)CD25(-)CD45RA(-) T cells. In summary, our findings show that ovarian carcinoma cells are able to induce expression of FOXP3 and exhibit suppressive ability in activated naïve T cells by producing soluble substances, and multiple cytokines involve in the induction of FOXP3 expression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673890     DOI: 10.1111/j.1349-7006.2009.01286.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  10 in total

1.  Blood lymphocyte blastogenesis in patients with thyroid dysfunction: ex vivo response to mitogen activation and cyclosporin A.

Authors:  Garyphallia Papaioannou; Fotios V Michelis; Konstantinos Papamichael; Helen Karga; Ekaterini Tiligada
Journal:  Inflamm Res       Date:  2010-10-24       Impact factor: 4.575

2.  EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer.

Authors:  Suryavathi Viswanadhapalli; Yiliao Luo; Gangadhara R Sareddy; Bindu Santhamma; Mei Zhou; Mengxing Li; Shihong Ma; Rajni Sonavane; Uday P Pratap; Kristin A Altwegg; Xiaonan Li; Annabel Chang; Alejandra Chávez-Riveros; Kalarickal V Dileep; Kam Y J Zhang; Xinlei Pan; Ramachandran Murali; Marek Bajda; Ganesh V Raj; Andrew J Brenner; Vijaya Manthati; Manjeet K Rao; Rajeshwar R Tekmal; Hareesh B Nair; Klaus J Nickisch; Ratna K Vadlamudi
Journal:  Mol Cancer Ther       Date:  2019-05-29       Impact factor: 6.261

3.  Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1.

Authors:  Xiang-Liang Yuan; Lei Chen; Tong-Tong Zhang; Yan-Hui Ma; Yun-Lan Zhou; Yan Zhao; Wei-Wei Wang; Ping Dong; Liang Yu; Yan-Yun Zhang; Li-Song Shen
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

4.  Cancer Stem Cells: An Ever-Hiding Foe.

Authors:  Jacek R Wilczyński
Journal:  Exp Suppl       Date:  2022

5.  Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.

Authors:  Cristina Di Giorgio; Silvia Marchianò; Elisabetta Marino; Michele Biagioli; Rosalinda Roselli; Martina Bordoni; Rachele Bellini; Ginevra Urbani; Angela Zampella; Eleonora Distrutti; Annibale Donini; Luigina Graziosi; Stefano Fiorucci
Journal:  Front Oncol       Date:  2022-06-30       Impact factor: 5.738

Review 6.  Targeting LIF/LIFR signaling in cancer.

Authors:  Suryavathi Viswanadhapalli; Kalarickal V Dileep; Kam Y J Zhang; Hareesh B Nair; Ratna K Vadlamudi
Journal:  Genes Dis       Date:  2021-04-29

7.  Adoptive T-Cell Therapy for Solid Tumors.

Authors:  Oladapo Yeku; Xinghuo Li; Renier J Brentjens
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

8.  Plasmid-encoded NP73-102 modulates atrial natriuretic peptide receptor signaling and plays a critical role in inducing tolerogenic dendritic cells.

Authors:  Weidong Zhang; Xueqin Cao; Dongqing Chen; Jia-Wang Wang; Hong Yang; Wenshi Wang; Subhra Mohapatra; Gary Hellermann; Xiaoyuan Kong; Richard F Lockey; Shyam S Mohapatra
Journal:  Genet Vaccines Ther       Date:  2011-01-10

9.  Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment.

Authors:  Oladapo O Yeku; Terence J Purdon; Mythili Koneru; David Spriggs; Renier J Brentjens
Journal:  Sci Rep       Date:  2017-09-05       Impact factor: 4.379

Review 10.  Cytokines as an important player in the context of CAR-T cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications.

Authors:  Caio Raony Farina Silveira; Amanda Cristina Corveloni; Sâmia Rigotto Caruso; Nathália Araújo Macêdo; Natália Moscheta Brussolo; Felipe Haddad; Taisa Risque Fernandes; Pamela Viani de Andrade; Maristela Delgado Orellana; Renato Luiz Guerino-Cunha
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.